<DOC>
	<DOCNO>NCT02001701</DOCNO>
	<brief_summary>Vitreomacular adhesion cause symptom blurry vision , distortion , double vision . It due abnormal separation vitreous gel surface retina macula . The current , gold-standard treatment condition involve surgery perform operating room involve risk bleeding , infection , cataract , retinal detachment . It previously show less invasive intravitreal injection gas bubble perform office may also treat vitreomacular adhesion less risk surgery . The purpose study determine effect office-based injection intravitreal gas bubble treatment symptomatic vitreomacular adhesion .</brief_summary>
	<brief_title>Intravitreal Gas Vitreomacular Adhesion</brief_title>
	<detailed_description>Symptomatic vitreomacular adhesion ( sVMA ) , also know Vitreomacular traction ( VMT ) think occur due anomalous incomplete posterior vitreous detachment ( PVD ) .1 Typical symptom VMT include decreased reading vision metamorphopsia . Ultra-high resolution spectral-domain optical coherence tomography ( SD-OCT ) greatly enhance understanding spectrum vitreomacular interface disorder range focal adhesion , macular cyst , impend macular hole , full thickness macular hole , lamellar hole , epiretinal membrane.2 Generally , par plana vitrectomy ( PPV ) surgery prefer treatment many condition high success rates.3 However , surgical intervention without risk include potential infection , retinal detachment , cataract progression , patient discomfort post-operative prone positioning case macular hole.4 Despite high success rate vitrectomy , risk surgery lead researcher search non-surgical treatment VMT pharmacologic vitreolysis . Ocriplasmin ( JetreaTM , ThromboGenics , Inc. Iselin , NJ ) recently approve United States Food &amp; Drug Administration ( FDA ) October 2012 non-surgical , pharmacologic agent treatment symptomatic VMA.5 Pooled data two phase III clinical trial ocriplasmin ( MIVI-TRUST ) 5 demonstrate approximately 26 % eye treat single intravitreal injection ocriplasmin ( 125 ug ) compare 10 % eye treat vehicle alone ( placebo ) result resolution VMA OCT 28 day . Potential side effect ocriplasmin include transient floater , zonular instability , transient vision loss.6 Although primary outcome study achieve statistically significant result compare placebo , less robust result compare surgical intervention associate high cost medication lead retina specialist question clinical utility medication . Previous small case series ' demonstrated intravitreal gas bubble injection alone ( i.e . pneumatic vitreolysis ) may lead macular hole closure induction PVD.7-9 Additional small case series ' show intravitreal gas bubble alone may induce PVD patient non-proliferative diabetic retinopathy10 diabetic macular edema11 nearly 100 % case . One small case series show intravitreal gas bubble combination anti-vascular endothelial growth factor agent cause resolution VMA patient wet macular degeneration 4/4 ( 100 % ) eyes.12 However , paucity literature specific treatment isolated VMT intravitreal gas alone . Recently , Rodriques et al13 demonstrate single intravitreal injection perfluoropropane ( C3F8 ) gas injection may cause VMT resolution 5/7 ( 70 % ) eyes isolate VMT 3/6 ( 50 % ) eye diabetic macular edema . Although initial study demonstrate efficacy , overall success rate procedure well visual acuity benefit limit due heterogeneous patient population . Pneumatic vitreolysis may offer potential safe , low cost , effective procedure may pose alternative treatment patient symptomatic vitreomacular adhesion . The purpose present study evaluate efficacy safety administration single intravitreal injection sulfa hexafluoride ( SF6 ) gas patient symptomatic vitreomacular adhesion without concomitant macular hole . Key difference present study Rodriques et al.10 use shorter act gas bubble ( SF6 v C3F8 ) inclusion homogenous patient population VMA alone .</detailed_description>
	<mesh_term>Tissue Adhesions</mesh_term>
	<criteria>Age 18 old Able provide write informed consent Patients Symptomatic Vitreomacular Adhesion ( sVMA ) define Clinical SDOCT finding : Clinical Findings : 1 . Symptoms : blur vision , double vision , metamorphopsia , micropsia 2 . Snellen Visual Acuity : &lt; 20/25 study eye SDOCT ( Cirrus , Car Zeiss Meditec , Dublin , CA ) Findings : 1 . Visible vitreous attachment within 1,500 um radius foveal center cause anteroposterior vitreofoveal traction associate microstructural retinal change 2 . See Figure 1 ( Image `` E '' ) representative candidate inclusion . Observation period 1 month prior intervention allow spontaneous resolution Figure 1 ( Images `` A '' , `` B '' , `` C '' , `` D '' , `` F '' , `` H '' , `` I '' ) Any Macular Hole Epiretinal Membrane History Diabetic Retinopathy ( nonproliferative , proliferative , and/or diabetic macular edema ) Macular Degeneration Retinal vascular occlusion Aphakia High myopia ( &gt; 8 diopter ) Uncontrolled glaucoma Vitreous Opacification Retinal tear retinal detachment Vitrectomy surgery Macular laser Figure 1 : Refer follow article : Stalmans P , Duker JS , Kaiser PK , et al . OCTBased Interpretation Vitreomacular Interface Indications Pharmacologic Vitreolysis . Retina ; 2013 : Epub ahead print</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>vitreomacular adhesion</keyword>
	<keyword>vitreomacular traction</keyword>
	<keyword>macular hole</keyword>
	<keyword>epiretinal membrane</keyword>
	<keyword>intravitreal gas</keyword>
	<keyword>sulfahexafluoride gas</keyword>
	<keyword>perfluoropropane gas</keyword>
	<keyword>ocriplasmin</keyword>
	<keyword>vitrectomy</keyword>
</DOC>